多发性硬化症的治疗结果,使用缩短和延长的间隔服用ocrelizumab
Antonia McLean1, Simon Arnett1, Joshua Yap1
1Department of Neurology, Gold Coast University Hospital, Southport QLD 4215, Australia.
Multiple sclerosis and related disorders
|July 30, 2025
概括
针对多发性硬化症 (MS) 患者的减少奥克雷利祖马布剂量,与标准剂量相比,显示出类似的临床和放射性结果. 这表明修改后的ocrelizumab疗法对于pwMS是安全有效的.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 由于感染风险和医院接入挑战,Ocrelizumab的剂量在COVID-19大流行期间被修改为患有多发性硬化症 (pwMS) 的人.
- 实施了降低剂量 (RD) 和延长剂量间隔 (EID),偏离标准剂量 (SD).
- 这项研究旨在比较这些修改后的疗法对SD的有效性和安全性.
研究的目的:
- 在pwMS中评估减少ocrelizumab剂量 (RD) 和延长剂量间隔 (EID) 的临床和放射性结果.
- 评估修改后的ocrelizumab剂量策略的安全性.
- 将这些结果与标准剂量 (SD) 在现实环境中进行比较.
主要方法:
- 从2018年1月1日至2024年1月1日期间接受了ocrelizumab治疗的113名pwMS的回顾性数据收集.
- 对临床复发,MRI病变,B细胞和免疫球蛋白水平的分析.
- 计算年度复发风险,并对SD,RD和EID组进行比较.
主要成果:
- 在SD,RD和EID疗法之间没有观察到临床或放射性结果的显著差异.
- 与SD相比,EID更频繁地发生了B细胞重组.
- 在RD和EID时,发现了较高免疫球蛋白水平的非显著趋势.
结论:
- 修改后的ocrelizumab剂量策略 (RD和EID) 没有影响pwMS的临床或放射性结果.
- 这些发现支持了减少对ocrelizumab暴露的潜在疗效和安全性.
- 需要进一步的前性研究来探索MS管理中的这些剂量策略.
相关概念视频
Rational Dosage Regimen: Maintenance Dose and Loading Dose
4.4K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
4.4K
Dosage Regimen: Fixed Dose
2.0K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
2.0K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
271
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
271
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
203
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
203
Drug Dosage Regimen: Overview
3.8K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.8K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
235
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
235


